Socrates E Papapoulos

Summary

Affiliation: Leiden University Medical Center
Country: The Netherlands

Publications

  1. pmc Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment
    A H van Lierop
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    J Clin Endocrinol Metab 97:E1953-7. 2012
  2. pmc Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension
    Socrates Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 27:694-701. 2012
  3. doi request reprint Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis
    Socrates Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Nat Clin Pract Endocrinol Metab 4:514-23. 2008
  4. doi request reprint Use of bisphosphonates in the management of postmenopausal osteoporosis
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Ann N Y Acad Sci 1218:15-32. 2011
  5. ncbi request reprint Who will benefit from antiresorptive treatment (bisphosphonates)?
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Best Pract Res Clin Rheumatol 19:965-73. 2005
  6. ncbi request reprint Bisphosphonate actions: physical chemistry revisited
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Bone 38:613-6. 2006
  7. ncbi request reprint Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Osteoporos Int 16:468-74. 2005
  8. ncbi request reprint Acquired resistance to bisphosphonates in Paget's disease of bone
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 21:P88-91. 2006
  9. pmc Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate
    S E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Ann Rheum Dis 66:853-8. 2007
  10. doi request reprint Bisphosphonates: how do they work?
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Best Pract Res Clin Endocrinol Metab 22:831-47. 2008

Collaborators

Detail Information

Publications48

  1. pmc Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment
    A H van Lierop
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    J Clin Endocrinol Metab 97:E1953-7. 2012
    ..Sclerostin is an osteocyte-produced negative regulator of bone formation, which is up-regulated by glucocorticoids in mice...
  2. pmc Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension
    Socrates Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 27:694-701. 2012
    ..Five-year denosumab treatment of women with postmenopausal osteoporosis maintained BTM reduction and increased BMD, and was associated with low fracture rates and a favorable risk/benefit profile...
  3. doi request reprint Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis
    Socrates Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Nat Clin Pract Endocrinol Metab 4:514-23. 2008
    ..However, the optimum duration of PTH administration, as well as the efficacy of such regimens in reducing the risk of fractures, remain to be determined...
  4. doi request reprint Use of bisphosphonates in the management of postmenopausal osteoporosis
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Ann N Y Acad Sci 1218:15-32. 2011
    ..Selection of bisphosphonates for the treatment of individuals should be based on a careful review of efficacy data, a risk profile of the bisphosphonate, and values and preferences of the patient...
  5. ncbi request reprint Who will benefit from antiresorptive treatment (bisphosphonates)?
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Best Pract Res Clin Rheumatol 19:965-73. 2005
    ..Such studies may help to formulate treatment recommendations according to the risk of the individual patient...
  6. ncbi request reprint Bisphosphonate actions: physical chemistry revisited
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Bone 38:613-6. 2006
  7. ncbi request reprint Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Osteoporos Int 16:468-74. 2005
    ..The overall reduction is consistent among different patient populations...
  8. ncbi request reprint Acquired resistance to bisphosphonates in Paget's disease of bone
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 21:P88-91. 2006
  9. pmc Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate
    S E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Ann Rheum Dis 66:853-8. 2007
    ..Prolongation of the drug-free interval beyond 2 weeks should be compensated by a dose higher than the cumulative daily dose...
  10. doi request reprint Bisphosphonates: how do they work?
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Best Pract Res Clin Endocrinol Metab 22:831-47. 2008
    ..Current studies address questions related primarily to the pharmacological properties of these compounds that are essential for their optimal clinical use, such as for example long-term safety and efficacy...
  11. doi request reprint Targeting sclerostin as potential treatment of osteoporosis
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Ann Rheum Dis 70:i119-22. 2011
    ..In initial human studies, a single injection of the antibody to postmenopausal women increased serum P1NP and transiently decreased serum CTX. Clinical phase II studies with this antibody are currently underway...
  12. ncbi request reprint Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer
    Jeroen T Buijs
    Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Res 67:8742-51. 2007
    ..Because exogenous BMP7 can still counteract the breast cancer growth at the primary site and in bone, BMP7 may represent a novel therapeutic molecule for repression of local and bone metastatic growth of breast cancer...
  13. ncbi request reprint Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases
    Serge C L M Cremers
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 20:1543-7. 2005
    ..Relationships between skeletal retention of pamidronate and rate of bone resorption are complex and depend on previous treatment and the total amount of retained bisphosphonate...
  14. doi request reprint Inhibition of bone resorption and growth of breast cancer in the bone microenvironment
    Jeroen T Buijs
    Department of Endocrinology, Leiden University Medical Center, C4 R, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Bone 44:380-6. 2009
    ..However, interference with the bone micro-environmental growth support could still be of therapeutic relevance when given to patients early in the course of bone metastatic disease...
  15. doi request reprint Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover
    Antoon H van Lierop
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 26:2804-11. 2011
    ..Further studies are needed to clarify the role of sclerostin on bone resorption...
  16. doi request reprint Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover
    Maria P Yavropoulou
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    Bone 51:153-7. 2012
    ..These increased levels may be due to a compensatory response to the increased number of osteoblasts at affected skeletal sites and may contribute to the increased bone resorption in patients with PC ...
  17. ncbi request reprint Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease
    Serge C L M Cremers
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    Osteoporos Int 16:1727-30. 2005
    ..This adequacy is confirmed by appropriate suppression of bone resorption and increase in lumbar spine BMD. These data hold significant implications for the clinical management of patients with Crohn's disease and osteoporosis...
  18. ncbi request reprint Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer
    Vidija Soerdjbalie-Maikoe
    Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Nucl Med Mol Imaging 31:958-63. 2004
    ..Our data suggest that there is still a place for bone scintigraphy in the management of hormone-refractory prostate cancer...
  19. ncbi request reprint Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension
    Caroline Brumsen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    J Bone Miner Res 17:1057-64. 2002
    ..One hundred fifty milligrams daily of pamidronate is an effective and safe treatment of women and men with established osteoporosis...
  20. ncbi request reprint Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo
    Gabri van der Pluijm
    Department of Endocrinology, Leiden University Medical Center, Leiden, Netherlands
    Cancer Res 65:7682-90. 2005
    ..Inhibition of bone turnover may represent a useful adjuvant therapy especially for cancer patients at risk to develop bone metastasis...
  21. pmc BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo
    Jeroen T Buijs
    Department of Urology, Leiden University Medical Center, J3 100, P O Box 9600, 2300 RC Leiden, The Netherlands
    Am J Pathol 171:1047-57. 2007
    ..Thus, BMP7 can still counteract the epithelial-to-mesenchymal transition process in the metastatic tumor, positioning BMP7 as a novel therapeutic molecule for treatment of metastatic bone disease...
  22. ncbi request reprint SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
    Rutger L van Bezooijen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Cytokine Growth Factor Rev 16:319-27. 2005
    ..The exclusive bone phenotype of good quality of patients with sclerosteosis and Van Buchem disease and the specific localization of sclerostin make it an attractive target for the development of bone forming therapeutics...
  23. ncbi request reprint Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study
    Marelise E M W Eekhoff
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 19:566-70. 2004
    ..Subjects with raised and normal ALP from a population cohort were matched (1 in 6, total 548), and radiographs were taken. ALP was an excellent marker of the disease (RR, 10.9), but the majority of those affected had normal ALP...
  24. ncbi request reprint SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development
    Rutger L van Bezooijen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Dev Dyn 236:606-12. 2007
    ..Activity of both signaling pathways was already down-regulated before induction of SOST expression...
  25. ncbi request reprint Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy
    Marelise E M W Eekhoff
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Bone 33:831-8. 2003
    ..In addition, we identified and quantified determinants of the response to bisphosphonate that can help in improving the management of patients with Paget's disease with bisphosphonates...
  26. doi request reprint Glucocorticoids are not always deleterious for bone
    Antoon H J M van Lierop
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 25:2796-800. 2010
    ..The exact mechanism by which sclerostin may be involved in the regulation of bone resorption is as yet to be explored...
  27. doi request reprint Low-energy fractures of the humeral shaft and bisphosphonate use
    Maria P Yavropoulou
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 27:1425-31. 2012
    ..Our results show that low-energy fractures of the humeral shaft with "atypical" radiographic characteristics are infrequent and are not associated with the use of bisphosphonates or glucocorticoids...
  28. ncbi request reprint Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis
    Serge C L M Cremers
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    J Rheumatol 31:1732-7. 2004
    ..We investigated the whole body retention (WBR) of pamidronate and its relationship to bone resorption and cartilage degradation in patients with active RA...
  29. pmc Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
    Rutger L van Bezooijen
    Department of Endocrinology, C4 R, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Netherlands
    J Exp Med 199:805-14. 2004
    ..Its unique localization and action on osteoblasts suggest that sclerostin may be the previously proposed osteocyte-derived factor that is transported to osteoblasts at the bone surface and inhibits bone formation...
  30. doi request reprint Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features
    Andrea Giusti
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Bone 48:966-71. 2011
    ..1% of all femoral fractures), compared to ordinary ST/FS fractures are more frequent in bisphosphonate users, but equally occur in patients never treated with bisphosphonates...
  31. ncbi request reprint Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management
    Rob C M Pelger
    Department of Urology, Leiden University Medical Center, The Netherlands
    Bone 36:1-5. 2005
    ..In this malignancy in which metastases have a predilection for bone, failure to recognize osteomalacia can only result in significantly increasing the burden of skeletal complications...
  32. doi request reprint Bisphosphonate therapy in children with secondary osteoporosis
    Socrates E Papapoulos
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Horm Res Paediatr 76:24-7. 2011
    ..However, results obtained in adults cannot be readily extrapolated to children due to differences in the pathophysiology and progression of the disease as well as in the pharmacokinetics of bisphosphonates...
  33. doi request reprint Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies
    Andrea Giusti
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
    Bone 47:169-80. 2010
    ....
  34. ncbi request reprint Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy
    Caroline Brumsen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    J Bone Miner Res 17:567-9. 2002
  35. ncbi request reprint Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone
    Serge C L M Cremers
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 18:868-75. 2003
    ..Such approaches can lead to improved patient care and individualization of treatment of Paget's disease with bisphosphonates...
  36. ncbi request reprint Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis
    Serge C L M Cremers
    Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, The Netherlands
    Clin Pharmacokinet 44:551-70. 2005
    ..Recently, pharmacokinetic/pharmacodynamic models for response to bisphosphonates have been described and, at present, some of them are being used in the design of bisphosphonate regimens with long drug-free intervals...
  37. ncbi request reprint Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation
    Rutger L van Bezooijen
    Department of Endocrinology and Metabolic Diseases, Leiden Univerity Medical Center, Ther Netherlands
    J Bone Miner Res 22:19-28. 2007
    ..It inhibits BMP-stimulated bone formation both in vitro and in vivo but has no direct effect on BMP signaling. Instead, sclerostin inhibits Wnt signaling that is required for BMP-stimulated osteoblastic differentiation...
  38. doi request reprint Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene
    Polyzois Makras
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
    J Clin Endocrinol Metab 93:1386-9. 2008
    ..X-linked hypophosphatemic rickets (XLH) is characterized by hypophosphatemia and growth retardation. Early diagnosis and treatment improve growth...
  39. doi request reprint Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers
    Antoon H van Lierop
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 28:848-54. 2013
    ..The small amounts of sclerostin produced by patients with VBD may explain their milder phenotype compared to that of patients with sclerosteosis, in whom serum sclerostin is undetectable...
  40. doi request reprint Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?
    Janneke E Witteveen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Eur J Endocrinol 166:55-60. 2012
    ..In patients with primary hyperparathyroidism (PHPT), data on the relationship between PTH and FGF23 are scarce and not always concordant...
  41. ncbi request reprint Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A
    Martine M L Deckers
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
    Endocrinology 143:1545-53. 2002
    ..In conclusion, VEGF-A produced by osteoblasts in response to BMPs is not involved in osteoblast differentiation, but couples angiogenesis to bone formation...
  42. ncbi request reprint Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein
    Zhi Chao Dang
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, The Netherlands
    J Biol Chem 278:962-7. 2003
    ..As a result, the balance between activated ERs and PPARgamma determines the biological effects of genistein on osteogenesis and adipogenesis. Our findings may explain distinct effects of genistein in different tissues...
  43. ncbi request reprint Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice
    Martine M L Deckers
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
    J Bone Miner Res 17:998-1007. 2002
    ..On the other hand, our results confirm that bisphosphonates can be used safely in the treatment of disorders that affect the growing skeleton, such as in juvenile osteoporosis...
  44. ncbi request reprint Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton
    Vidya Soerdjbalie-Maikoe
    Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Nucl Med Mol Imaging 29:494-8. 2002
    ..The use of these agents opens new avenues in the difficult management of patients with advanced prostate cancer who are most at risk of developing SCC...
  45. ncbi request reprint Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
    Kenneth E S Poole
    MRC Bone Research Group, Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    FASEB J 19:1842-4. 2005
    ..In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture...
  46. ncbi request reprint Bone mineral density in sclerosteosis; affected individuals and gene carriers
    Jessica C Gardner
    Division of Human Genetics, Faculty of Health Sciences, University of Cape Town, South Africa
    J Clin Endocrinol Metab 90:6392-5. 2005
    ..In the present study we assessed the effect of variable expression of the genetic defect on bone mineral density (BMD) in patients and carriers of the determinant gene...
  47. ncbi request reprint Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption
    John M Sanders
    Department of Chemistry, 600 South Mathews Avenue, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
    J Med Chem 48:2957-63. 2005
    ..As such, they represent useful new leads for the discovery of new bone resorption, antiinfective and anticancer drugs...
  48. ncbi request reprint Prolonged bisphosphonate release after treatment in children
    Socrates E Papapoulos
    N Engl J Med 356:1075-6. 2007